Blog

Check out the state of immunotherapy in resectable NSCLC – FDA Oncology

Photo taken from FDA Oncology/X

May 27, 2024, 07:35

Check out the state of immunotherapy in resectable NSCLC – FDA Oncology

FDA Oncology shared a post on X:

“Check out the state of immunotherapy in resectable NSCLC: This ASCO Ed Book article includes views from academia & FDA. Good warmup for ASCO 24 Education Session ‘Integrating Immunotherapy into Early-Stage Lung Cancer’ on June 2.

→ Ongoing trials of immunotherapy and RT for early stage NSCLC.
→ Clinical implications of recent advances in immunotherapy for resectable NSCLC.
→ Current trial designs assessing immunotherapy in resectable NSCLC: challenges, opportunities.”

View additional information.
Source: FDA Oncology/X
.

academia ASCO 24 ASCO Ed Book cancer Challenges clinical implications early stage NSCLC Education Session FDA FDA Oncology immunotherapy Integrating Immunotherapy into Early-Stage Lung Cancer OncoDaily Oncology ongoing trials opportunities recent advances resectable NSCLC RT trial designs

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity